← Eichor
Study identifier: NCT07027072 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease

Condition: Mild Cognitive Impairment (MCI) · Mild Dementia · Alzheimer's Disease  ·  Sponsor: NeuroBiogen Co., Ltd

PhasePhase 2
Planned participants114
Who can joinAll sexes, 50 Years to 85 Years
Healthy volunteersNo

About this study

A randomized, double-blind, placebo-controlled, dose-finding Phase 2a clinical trial will be conducted to evaluate the efficacy and safety of KDS2010 in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) and mild dementia due to Alzheimer's disease. Based on preliminary efficacy observed in the Phase 1 clinical trial, a clinical trial will be conducted in Korea. Eligible patients diagnosed with MCI or mild Alzheimer's disease will be stratified by disease stage (MCI/mild AD) prior to randomization. Subjects will be randomly assigned in a 1:1:1 ratio to either Treatment Group 1, Treatment Group 2, or the Control Group. The investigational product will be administered orally once daily for a duration of 24 weeks. Approximately 114 subjects will be enrolled, including an estimated 20% dropout rate, with 38 subjects assigned to each group (Treatment Group 1, Treatment Group 2, and Control Group). The objectives of the study are as follows: 1. Efficacy Objectives: Efficacy will be evaluated through changes in cognitive function, self-management, and daily living activities before and after administration of KDS2010. Biomarker analysis in plasma and in cerebrospinal fluid (CSF; optional) will also be conducted to explore treatment efficacy. 2. Safety Objectives: The safety and tolerability will be evaluated after administration of KDS2010. 3. Exploratory Objectives: The efficacy of Treatment Groups 1 and 2 compared to the Control group will be explored…

This description comes directly from the study's public registry record.

Talk to the study team

Yeonsil Moon, Professor  ·  +82)70-4018-8009  ·  neuro_reply@neurobiogen.com

Dayoung Kim, Professor

Always discuss trial participation with your own doctor first.

Locations (8)

Chonnam National Unversity HospitalGwangju, Gwangju, South KoreaRecruiting
Hanyang University Guri HospitalGuri-si, Gyeonggi-do, South KoreaRecruiting
The Catholic University of Korea St. Vincent's HospitalSuwon, Gyeonggi-do, South KoreaRecruiting
Ajou University HospitalSuwon, Gyeonggi-do, South KoreaRecruiting
Gachon University Gil Medical CenterIncheon, Incheon, South KoreaRecruiting
Hanyang University Seoul HospitalSeoul, Seoul, South KoreaRecruiting
Konkuk University Medical CenterSeoul, Seoul, South KoreaRecruiting
Asan Medical CenterSeoul, Seoul, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07027072